Da metabolismen forventes at ske ved peptidhydrolyse, forventes leversvigt ikke at påvirke farmakokinetikken af agalsidase alfa på en klinisk signifikant måde.
As metabolism is expected to occur by peptide hydrolysis, impaired liver function is not expected to affect the pharmacokinetics of agalsidase alfa in a clinically significant manner.